Medidata Solutions announced that Novella Clinical has expanded its use of Medidata products with the addition of Medidata Grants Manager®, the investigator site benchmarking tool. Grants Manager offers Novella a clear competitive advantage by enabling access to critical cost data to more accurately forecast trial costs as it serves sponsors outsourcing clinical trial activities. Grants Manager is designed to help users streamline site budget negotiations, ensure fair and reliable investigator payments, mitigate compliance risks, and reduce time of site enrollment.
Novella first partnered with Medidata in 2005 when it adopted Medidata Rave®, a system for electronic data capture, management, and analysis. Now, with the adoption of Grants Manager, Novella has access to Medidata’s unique PICAS® database—a clinical cost database derived from negotiated agreements between sponsors, investigators and CROs—which will bring insight into industry-benchmarked investigator site costs. Grants Manager offers access to data from nearly a quarter million grants and contracts and more than 27,000 protocols in over 1,400 indications.
As a Medidata Services Partner, Novella is accredited in Medidata Rave to provide a full suite of Rave-related services, including end-user training, user and site administration, study build, reporting, outputs, integrations, and migrations. The addition of Grants Manager into Novella’s clinical systems environment further enables it to provide services that streamline and enhance its customers’ clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.